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ABSTRACT
Background: PD is a complex polygenic disorder. In
recent years, several genes from the endocytic
membrane-trafficking pathway have been suggested to
contribute to disease etiology. However, a systematic
analysis of pathway-specific genetic risk factors is yet to
be performed.
Objectives: To comprehensively study the role of the
endocytic membrane-trafficking pathway in the risk of PD.
Methods: Linkage disequilibrium score regression was
used to estimate PD heritability explained by 252 genes
involved in the endocytic membrane-trafficking pathway
including genome-wide association studies data from
18,869 cases and 22,452 controls. We used pathway-
specific single-nucleotide polymorphisms to construct a
polygenic risk score reflecting the cumulative risk of com-
mon variants. To prioritize genes for follow-up functional
studies, summary-data based Mendelian randomization
analyses were applied to explore possible functional
genomic associations with expression or methylation
quantitative trait loci.
Results: The heritability estimate attributed to endocytic
membrane-trafficking pathway was 3.58% (standard
error = 1.17). Excluding previously nominated PD endo-
cytic membrane-trafficking pathway genes, the missing
heritability was 2.21% (standard error = 0.42). Random
heritability simulations were estimated to be 1.44%
(standard deviation = 0.54), indicating that the unbiased
total heritability explained by the endocytic membrane-
trafficking pathway was 2.14%. Polygenic risk score
based on endocytic membrane-trafficking pathway
showed a 1.25 times increase of PD risk per standard
deviation of genetic risk. Finally, Mendelian randomiza-
tion identified 11 endocytic membrane-trafficking
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pathway genes showing functional consequence associ-
ated to PD risk.
Conclusions: We provide compelling genetic evidence
that the endocytic membrane-trafficking pathway plays a
relevant role in disease etiology. Further research on this
pathway is warranted given that critical effort should be
made to identify potential avenues within this biological
process suitable for therapeutic interventions. © 2019
International Parkinson and Movement Disorder Society
Key Words: endocytosis; genetic risk; heritability;
Parkinson’s disease; polygenic risk score
Parkinson’s disease (PD) is a progressive neurodegen-
erative disorder clinically characterized by the manifes-
tation of motor disturbances such as bradykinesia,
rigidity, tremor, and a wide range of nonmotor symp-
toms. Disease is caused by the death of the dopaminer-
gic neurons in the SN with the consequent deficit of
striatal dopamine.1 The etiology of PD is complex,
including genetic, epigenetic, and environmental fac-
tors. Familial PD accounts for less than 10% of the
total cases, mostly attributed to monogenic forms with
autosomal-dominant (including SNCA, LRRK2, and
VPS35) or autosomal-recessive pattern of inheritance,
such as PARKIN, PINK1, and DJ-1, among others.2,3
However, the vast majority of the disease is considered
to be sporadic, likely caused by the cumulative effect of
multiple common or rare variants of small or moderate
effect sizes in addition to other unknown environmental
and stochastic factors.
Over the last two decades, extensive work in genetics
has uncovered up to 92 common risk loci associated
with idiopathic PD.4 As expected from complex diseases,
the PD-related signals identified to date only account for
a small proportion of the total phenotypic variation,
defined as heritability.5 It is estimated that only around
10% to 15% of the overall heritable risk of PD is
explained by current genome-wide association studies
(GWAS).4 The most plausible explanation for the “miss-
ing heritability” might be small effect sizes of the yet to
be discovered risk loci which do not reach GWAS signifi-
cance, as well as structural genomic and rare variation
poorly covered by current technology.6 Undoubtedly,
the estimated heritability in PD suggests that a significant
amount of risk has not been uncovered yet.
Aligned with the genetic discoveries, a big effort has
been made to identify how those genes interact within
biological pathways to elucidate the cellular and molecu-
lar processes that could explain the neurodegenerative
mechanism.7 Recent findings point out that dysfunction
in the endosomal membrane-trafficking pathway
(EMTP) could be a driving force in the pathogenesis of
PD.8 The EMTP is a complex multistep pathway that
involves different process and organelles. First, cells
uptake macromolecules and other cargo from the extra-
cellular space to a group of organelles called early endo-
somes. From this point, internalized molecules can
recycle back to the plasma membrane directly or
through recycling endosomes. Alternatively, endocytosed
cargo can be retained in early endosomes that will eventu-
ally mature into late endosomes and fuse with lysosomes
to ensure cargo degradation. In parallel, proteins can also
traffic between endosomes and the Golgi apparatus (for a
review, see a previous work9). A substantial amount of
genetic variation in PD and parkinsonism previously
nominated genes has been associated with vesicle traffick-
ing by endosomal gene alterations,10 including monogenic
genes (VPS35,11 DNAJC613,18) and GWAS-nominated
genes (RAB7L1,12,13 SH3GL2,14 GAK,15,16 and
CHMP2B15,17). In addition, other well-known PD genes,
such as LRRK212,13 and PLA2G6, 18 seem to be linked
to the aforementioned pathway through their biological
interaction with EMPT genes. LRRK2 binds to
RAB7L112,13 and PLA2G6 interacts with VPS35 and
VPS26, although a clear role of these genes in the EMTP
is yet to be elucidated. The genes involved in the EMTP
play different roles within the pathway. For instance,
DNAJC6, SYNJ1, GAK, and SH3GL2 are linked to
clathrin-coated vesicles whereas VPS35, DNAJC13, or
RAB7L1 participate in recycling components from the
endosomes to the Golgi. Hence, it seems plausible that
other genes in that pathway could be involved in PD risk
and therefore account for the nonreported heritability.
Based on these premises, we aimed to benefit from a cel-
lular perspective to systematically explore the genetic con-
tribution of 252 endosomal membrane-trafficking–related
genes on the susceptibility for PD. We set out to study to
what extent common variation in these genes might play a
role on the genetic architecture of PD by performing
genome-wide heritability estimations and polygenic risk
versus disease status and age at onset in the International
Parkinson’s Disease Genomics Consortium (IPDGC)
GWAS data set. We also applied Mendelian randomization
to attempt to investigate possible functional genomic asso-
ciations between nominated variants of interest within this
pathway versus expression and methylation quantitative
trait loci. Finally, we used biological pathway analysis and
expression data from murine SN to point out the biological
contribution of the genetic findings.
Patients and Methods
Subjects
The IPDGC GWAS data set consisted of 41,321 indi-
viduals (18,869 cases and 22,452 controls) of European
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ancestry. Clinical and demographic characteristics of the
cohorts under study are shown in Supporting Informa-
tion Table S1. Additional details of these cohorts can be
found in Nalls and colleagues.4
No individuals with known pathogenic mutations
were excluded from following analyses. When the case
age at onset or control age at last exam was not pro-
vided, individuals were likewise included.
Genes Selection and Pathway Analysis
The EMTP is a general and extense pathway that
includes several subpathways. EMTP-related genes
under study were selected by using The Molecular Sig-
natures Database (MSigDB) of annotated gene set for
“endocytosis”19,20 based on the Kyoto Encyclopedia of
Genes and Genomes information (KEGG-endocytosis).
However, the gene list provided by KEGG was not
completely accurate and failed to represent some rele-
vant genes within the EMTP. In order to validate
whether each gene flagged as endocytosis was involved
in the EMTP, a detailed literature search was per-
formed. In addition, because the current research in the
EMTP is very dynamic and there are constantly new
discovered proteins involved in some aspects of the
pathway, we included relevant genes that have been
proved to participate in the EMPT, but were not nomi-
nated by KEGG. In addition, a thorough review of the
literature was performed using the terms
“endocytosis,” “endosome to Golgi retrograde
transport,” “endosomal maturation,” and “endosomal
recycling.” We have provided a table (Supporting
Information Table S2) that includes each gene involved
in our analysis with the literature source that refers
to. A total of 262 genes were flagged as “endocytic
membrane-trafficking” (Supporting Information
Table S2), of which 252 were autosomal and
10 spanned in chromosome X. The latter were
excluded for the following analyses because of lack of
data. The PANTHER web-based Classification System
was used to obtain the Top 10 significant enriched
Reactome Pathways with an adjusted false discovery
rate (FDR) P value <0.05. Additionally, we obtained
expression data from single-cell RNA sequencing per-
formed in 243 putative dopaminergic neurons at post-
natal days 28 to 56 from Slc6a3-Cre/tdTomato mice
(GSE76381).21 We applied an arbitrary selected thresh-
old of expression. Only genes with total expression
values across the 243 cells higher than 100 were nomi-
nated as expressed. Human genes were converted to
their ortholog genes using Mouse Genome Informatics
(MGI; http://www.informatics.jax.org; Supporting
Information Table S3). For Venn diagram visualiza-
tion, the online-based website http://bioinformatics.
psb.ugent.be/webtools/Venn/ and Inkscape software
(version 0.92.2; https://inkscape.org) were used.
Quality Control
Genome-Wide Association Data
Quality-control (QC) procedures in the IPDGC
GWAS data set have been previously described else-
where.4 In brief, samples with call rates <95% and
whose genetically determined sex from X chromosome
heterogeneity did not match that from clinical data
were excluded. Individuals exhibiting heterozygosity
greater than 6 standard deviations (SDs) from the pop-
ulation mean and samples of non-European ancestry
were not included. Individuals related at more than the
level of first cousin estimated from linkage pruned
genetic data on common variants were excluded (1 pro-
band from any family cluster was extracted randomly).
Regarding variant QC, variants exhibiting Hardy–
Weinberg equilibrium P value <1E-5 and missingness
rates >5% as well as palindromic single-nucleotide
polymorphisms (SNPs) were excluded from further ana-
lyses. Data were imputed using the Haplotype Refer-
ence Consortium (http://www.haplotype-reference-
consortium.org), under default settings with phasing
using the EAGLE option (https://www.nature.com/
articles/ng.3643 https://www.ncbi.nlm.nih.gov/pubmed/
27571263). VCFs were filtered for imputation quality
>0.30 for inclusion in analyses.
Heritability Analysis
In order to estimate the phenotypic variance of PD
explained by genes in the extended EMTP pathway, we
estimated heritability using linkage disequilibrium
(LD) score regression (LDSC).22,23 We used LDSC to
estimate heritability in this study because it requires
only summary-level data and is more computationally
efficient for larger data sets. We extracted EMTP
regions of interest from a meta-analysis of GWAS data
and then ran LDSC under default settings. Reference
LD scores were computed with the European ancestry
subset of the 1000 Genomes data for SNPs within
500 kilobase pairs (kb) of the SNP to be scored.
First, we estimated heritability explained by variants
in the whole set of EMTP genes and missing heritability
by excluding previously PD-associated, EMTP-related
genes. Subsequently, to evaluate significant enrichment
of heritability within our pathway of interest compared
to any similar set of genes, we resampled 50 random
sets of 252 genes in the same sample series (after
excluding EMTP genes and regions 250 kb from PD
GWAS loci). During resampling, we implemented the
exact sample LDSC analyses and extracted the herita-
bility per sampling iteration. Next, we calculated the
mean and SDs of the heritability across sampling itera-
tions. Finally, the mean heritability of our resampled
series was compared to the test set to determine
whether our previous estimates were significantly
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divergent from random sets of genes of similar size
using a t test.
In an attempt to explore the genes that contribute the
most to the estimated heritability, we performed the
Sequence Kernel Association Test (SKAT) in imputed
data adjusting by age, sex, and data subset membership
without applying any frequency filtering. Significance was
evaluated using 10,000 permutations at alpha = 0.001.
Polygenic Risk Profiles Versus Disease
Status and Age at Onset
For the risk-profiling analysis, we mirrored the work-
flow used in the most recent PD meta-analysis to date,4
with the exception that before running this analysis
pipeline, we extracted only genotypes from the pathway
of interest. In brief, PRS profiling is calculated tradi-
tionally based on weighted allele dose manner as per
previous work.25-32 We used the R package PRSice2.33
Permutation testing and P-value aware LD pruning was
used to identify best P thresholds in external GWAS
data to construct the PRS, allowing us to utilize vari-
ants below the common GWAS significance threshold
of 5E-08. External summary statistics utilized in this
phase of analysis included data from leave-one-out
meta-analyses that exclude the study in which the PRS
was being tested, avoiding overfitting/circularity to
some degree. LD clumping was implemented under
default settings (window size = 250 kb; r2 > 0.1), and
for each data set, 10,000 permutations were used to
generate empirical P estimates for each GWAS-derived
P threshold ranging from 5E-08 to 0.5, at a minimum
increment of 5E-08. Each permutation test in each data
set provided a Nagelkerke’s pseudo r2 after adjustment
for an estimated prevalence of 0.005 (aged population
estimate as per Gasser and colleagues)33 and study-
specific eigenvector 1 to 5, age, and sex as covariates.
GWAS-derived P threshold with the highest pseudo r2
was selected for further analysis. Summary statistics
were meta-analyzed using random effects (restricted/re-
sidual maximum likelihood) per study-specific data set
by using the R package PRSice-2.34
For the age at onset risk profiling, we performed simi-
lar analyses with the exception that we used age at
onset as a continuous variable.
Mendelian Randomization Analysis to Explore
Pathway-Specific Quantitative Trait Loci
We utilized two-sample Mendelian randomization to
investigate possible functional genomic associations
between nominated variants of interest in the EMTP
pathway versus expression and methylation patterns.
Quantitative trait loci (QTL) association summary
statistics across well-curated methylation and expres-
sion data sets from the SMR (http://cnsgenomics.com/
software/smr)35 were compared to PD outcome
summary statistics4 after extracting the pathway-specific
variants considered as the instrumental variables. These
include estimates for methylation and cis-expression
from the Genotype-Tissue Expression (GTEx) Consor-
tium (v6; whole blood and 10 brain regions),36 the Com-
monMind Consortium (CMC; dorsolateral prefrontal
cortex),37 the Religious Orders Study and Memory and
Aging Project (ROSMAP),38 and the Brain eQTL Alma-
nac project (Braineac; 10 brain regions),39 as reported
elsewhere. Furthermore, we studied expression patterns
in blood from the largest eQTL meta-analysis so far.40
Wald ratios were generated for each of the instrumen-
tal variable SNPs tagging a cis-QTL (probes within each
gene and meeting a QTL P value of at least 5E-8 in the
original QTL study) and for a methylation or expression
probe with a nearby gene. Linkage pruning and clump-
ing were carried out using default SMR protocols. With
each data type, P values per instrument substrate (gene-
level expression summaries for eQTLs and cis-gene
probe level for mQTLs) were adjusted by FDR.
Results
Pathway Analysis and Expression
of EMTP-Related Genes
EMTP variants from imputed data were extracted
from 252 genes selected as described in the Patients and
Methods section. Distribution of variants within the
EMTP in the IPDGC cohort are highlighted in Support-
ing Information Table S4. Gene Ontology analysis was
performed on these genes showing an enrichment for
trafficking-related biological processes such as lyso-
somal biogenesis, clathrin-mediated endocytosis, retro-
grade transport at the trans-Golgi network or vesicle-
mediated transport among others (Fig. 1A). Remark-
ably, 151 genes among the analyzed genes were found
expressed in dopaminergic neurons in adult mouse
brains (Fig. 1B).
Heritability Analysis
We measured heritability explained by the 252 genes
under study. EMTP genetic contribution to PD herita-
bility was estimated to be 3.58% (standard error
[SE] = 1.17). After excluding previously nominated PD
and parkinsonism genes related to the EMTP, including
DNAJC13, VPS35, DNAJC6, SYNJ1, SYT4, SYT11,
GAK, RAB7L1, CHMP2B, and SH3GL2, missing heri-
tability explained by EMTP-related genes was estimated
to be 2.21% (SE = 0.42). Reported heritability esti-
mates might be underestimated given that there are pos-
sibly rare variants within these genes poorly covered by
current genotyping technologies or lost after imputa-
tion. These estimates were significantly different from
50 randomly generated sets of 252 genes (t test,
P < 2.2E-16) giving a heritability estimate of 1.44%
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(SD = 0.54) and showing that the heritability enrich-
ment in the EMTP pathway is not likely by chance
(Supporting Information Fig. S1). After subtracting the
randomly generated heritability estimates (1.44%) that
might have biased our initial EMTP estimates, the
EMTP genetic contribution to PD heritability was esti-
mated to be 2.14%. When considering 22.9% as the
latest estimate of total heritability for PD using the
same methodological approach,4 the EMTP explains
roughly 9.34% of the overall heritability of PD.
Additionally, we explored what genes contributed to
a greater extent to the PD heritability estimates within
the EMTP. Nineteen genes surpassed multiple test cor-
rection after the SKAT analysis with FDR-adjusted
P values <0.05 (Supporting Information Table S5).
Only GAK has been previously associated with PD.
Polygenic Risk Profiles Versus Disease Status
and Age at Onset
EMTP risk profiling versus disease status was found
to be significantly associated with PD (random-effects
P value = 2.55E-12; beta = 0.227; SE = 0.032) and an
odds ratio of 1.20 per SD increase in the PRS from the
population mean (see Fig. 2 for forest plot showing
effect estimates within gene sets). Heterogeneity was
estimated at an I2 of 59.32% across all arrays. In
all data sets, the directionality of effect was similar.
The data obtained from the different data sets
strongly enhance the general conclusion for our study.
EMTP risk profiling versus age at onset was not
found to be significantly associated (random-effects
P value = 0.182).
Mendelian Randomization Analysis
to Explore Pathway-Specific QTL
We also tested a number of QTL resources across
varied tissues of interest to make functional inferences
relating to biological features that might be involved in
the genetic etiology of the disease. After adjustment for
FDR correction, 11 EMTP-related genes showed func-
tional consequence by two-sample Mendelian randomi-
zation in expression and methylation datasets (see
Table 1). Increased blood expression of VAMP4,
ARL8B, and GAK was found to be inversely associated
to PD risk, whereas a positive risk association was
found for RABGEF1, VAMP8, CLTCL1, and ITSN1.
Increased brain expression of SH3GL2 and GAK was
causally linked to PD risk whereas ARL8B expression
FIG. 1. Biological implication of EMPT genes in dopaminergic (DA) neurons. (A) Top 10 significant Enriched Reactome Pathways with an adjusted FDR
P value <0.05. Pathway enrichment analysis was performed using Panther. Only the top 10 enriched pathways were selected for visualization.
(B) Overlap between genes expressed in DA neurons and EMTP gene set. The EMTP human genes were transformed in their mouse homolog genes.
From the 252 total human genes, a total of 244 were found in mouse (Supporting Information Table S3). DA neuron gene expression was obtained from
GSE76381)21 after an arbitrary selected threshold of expression. [Color figure can be viewed at wileyonlinelibrary.com]
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exhibited a negative association. mQTL Mendelian ran-
domization analyses revealed eight CpG sites linked to
PD risk after multiple test correction. Increased methyl-
ation of GAK and HSPA1B was found to be positively
associated with disease whereas PLEKHM1 and VPS39
showed a negative directionality versus PD risk.
Discussion
The present study provides compelling evidence for
EMTP variation in PD risk. Using a set of pathway-
specific genes/variants, we demonstrate that the pheno-
typic variance attributed to this complex process con-
tributes to the heritability of PD outside of what is
explained by GWAS.
Genetic variance in PD has been estimated to be
~22.9%,4 and to date only a small proportion of the
total heritability has been explained.4 Our data show
that approximately 2.14% of the common variant heri-
tability in PD can be explained by genetic variants in
the EMTP, explaining roughly 9.34% of the overall
estimates in PD. Here, we have only included the tran-
scribed genes assuming the limitation that the heritabil-
ity residing in regulatory regions adjacent to the up- or
downstream of these genes is not included in this esti-
mate. The reported estimates suggest that there are
additional PD genes within the EMTP yet to be
discovered. Our results are in concordance with the
largest and most recent meta-analysis in PD, which
tested up to 10,651 biological pathways. Among these,
only 27 were enriched for PD associations after multi-
ple testing correction,4 and, notably, endosomal traf-
ficking was included with significant P value.
PRS has previously demonstrated how cumulative
small effect variants can contribute to PD risk and age
at onset.30 PRS has emerged as a probabilistic tool to
infer how independent loci with small effects can be
collapsed into a single numerical value useful in predict-
ing the risk of a disease. It has been successfully used to
dissect the genetic complexity of brain disorder and
quantify risk in many common complex conditions42,43
for early detection, prevention and therapeutics.44,45
Here, we assessed the overall cumulative contribution
of EMTP-specific loci/genes in PD risk through PRS
calculations. Our data show that the PRS based on
252 EMTP gene regions is associated with a 1.2 times
increased of PD risk per SD, confirming a cumulative
pathogenic effect of EMPT variants in PD.
When assessing whether the EMTP had any effect on
the age at onset (AAO), we did not find any significant
association. PD genetic studies using AAO as a predictor
report greater genetic burden with earlier AAO. 29,46
Linking specific phenotypic aspects of PD to pathways
constitutes a critical effort, but remains challenging
given that larger longitudinal cohorts of well clinically
FIG. 2. Polygenic Risk Score across EMTP. Forest plots of PRS estimates across cohorts. For each effect estimate, the size of the square is proportional to
the size of the study, with 95% confidence intervals as horizontal error bars. The random-effects estimates are represented by the red diamond, with fixed
effects in blue, and the centerline of each diamond representing the summary PRS estimate. The number of samples per cohort are reported as follows:
SHULMAN: 789 cases and 195 controls; MCGILL: 583 cases and 906 controls; SPAIN3: 2,120 cases and 1,333 controls; TUBI: 741 cases and 944 controls;
VANCE: 621 cases and 303 controls; OSLO: 476 cases and 462 controls; HBS: 541 cases and 743 controls; PDBP: 543 cases and 284 controls; FINLAND:
386 cases and 493 controls; and PPMI: 363 cases and 165 controls. [Color figure can be viewed at wileyonlinelibrary.com]
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characterized patients are necessary. We believe that the
PRS approach we report on here should be further
explored in other clinical outcomes related to PD.
Growing evidence has suggested that abnormalities in
endosomes or dysregulation in their trafficking plays an
important role in several neurological diseases such as
Alzheimer’s disease or Lewy body dementia.47,48 This
pathway is emerging as key to understanding the mech-
anisms underlying both protein degradation and neuro-
degeneration. We performed SKAT analysis in order to
nominate the genes that contribute the most to the risk
of PD within the EMTP. Nineteen genes were signifi-
cant after FDR correction, including PLEKHM1,
IQSEC3, GAK, VPS39, AMPH, SMURF1, CHMP1A,
AP2B1, VPS28, VAMP8, AP3B2, RABGEF1,
PLEKHG7, TBC1D15, AP4E1, AP2M1, STX8, ARF-
GAP2, and AP3M1. Interestingly, nine of them are
involved in cargo degradation and eight of them play a
role in cargo uptake, which strongly suggests that these
two subpathways are specially relevant for PD risk.
Only GAK has already been associated with PD risk
through GWAS,4,30,31 and for the remaining 18 genes
not identified in previous studies, only five, including
IQSEC3, VPS39, CHMP1A, AP3B2, and AP4E1, have
been associated with neurological disorders. For
instance, IQSEC3 protein expression is downregulated
in the brain of patients that suffer from autism and
schizophrenia,49 and loss-of-function mutations in
CHMP1A cause pontocerebellar hypoplasia and micro-
cephaly.50 Autosomal-recessive mutations in AP3B2
cause early-onset epileptic encephalopathy,51 and a
mutation in AP4E1 has been found in a familiar case of
spastic paraplegia.52 Furthermore, QTL analysis using
Mendelian randomization indicates that five genes
among the ones nominated by SKAT showed functional
relevance associated with PD (PLEKHM1, VPS39,
GAK, VAMP8, and RABGEF1).
The present study shows that EMTP genes contribute
to PD risk. However, we are aware of some limitations.
First, our work is restricted by the sensitivity of array-
based genotyping methods used to calculate heritability.
Likewise, heritability estimates might be biased, appear-
ing lower than what should be expected. The remaining
variance in PD etiology not ascribed to the EMTP-
identified heritable factors suggests a contribution of
joint effects of rare and structural variants poorly cov-
ered by current genotyping technology. Therefore, fur-
ther comprehensive studies are needed to identify novel
variants within the EMTP that are relevant for disease.
Additionally, there may be some selection bias in the
PRS, although the meta-analysis suggests consistent
effect estimates across studies.
The endosomal trafficking membrane system is a
complex and dynamic process where internalized pro-
teins, receptors, and ligands interact and move between
organelles in order to fulfill the cell’s needs. Here, we
point to PD, at least to some extent, as an endosomal
membrane-trafficking disease. This study demonstrates
the contribution of this unknown pathway to the oligo-
genic nature of PD and highlights the importance of
pathway-based comprehensive approaches as a way to
prioritize functional studies. Following the most recent
meta-analysis,4 pathway analysis established that the
nominated candidate genes were linked to autophagy,
mitochondrial biology, immune response, and lyso-
somal function. We envisage that our methodology
TABLE 1. Significant functional associations for EMTP-related genes by two-sample Mendelian randomization
Gene Probe Beta SE P Adjusted Data Source Analyte Top QTL SNP Chr Bp
VAMP4 ILMN_1761363 –0.121 0.022 5.21E-06 Expression40 Blood rs10913529 1 171679465
VAMP4 ILMN_1804676 –0.156 0.029 5.21E-06 Expression40 Blood rs11580522 1 171720978
ARL8B ILMN_1752837 –0.174 0.045 4.80E-03 Expression40 Blood rs4499578 3 5167618
GAK ILMN_1813775 –0.090 0.025 1.12E-02 Expression40 Blood rs6964 4 843184
RABGEF1 ILMN_2230577 0.266 0.080 1.94E-02 Expression40 Blood rs4718424 7 66376095
VAMP8 ILMN_2190084 0.041 0.012 2.20E-02 Expression40 Blood rs1058588 2 85808871
ITSN1 ILMN_1718769 0.077 0.025 3.66E-02 Expression40 Blood rs2251854 21 35056247
CLTCL1 ILMN_1694584 0.066 0.022 3.88E-02 Expression40 Blood rs2854643 22 19189706
SH3GL2 ENSG00000107295 0.252 0.045 2.45E-06 Expression41 Brain rs10756899 9 17684784
GAK ENSG00000178950 0.508 0.103 3.47E-05 Expression41 Brain rs11248057 4 906131
ARL8B ENSG00000134108 –0.033 0.010 1.90E-02 Expression41 Brain rs6787725 3 5201054
GAK cg14517359 0.158 0.030 1.51E-05 Methylation41 Brain rs3775127 4 886061
HSPA1B cg00970279 0.048 0.010 4.99E-05 Methylation41 Brain rs506770 6 31785228
HSPA1B cg16237409 0.051 0.011 4.99E-05 Methylation41 Brain rs506770 6 31785228
PLEKHM1 cg06925179 –0.094 0.026 4.92E-03 Methylation41 Brain rs4523963 17 43570226
GAK cg23992470 0.093 0.027 1.20E-02 Methylation41 Brain rs114066161 4 825635
PLEKHM1 cg04703951 –0.144 0.043 1.20E-02 Methylation41 Brain rs4523963 17 43570226
VPS39 cg04726019 –0.092 0.028 1.28E-02 Methylation41 Brain rs57393446 15 42494536
GAK cg26978381 0.119 0.037 1.38E-02 Methylation41 Brain rs2306253 4 884475
P adjusted = adjusted false discovery rate P value after performing Mendelian randomization between QTL resources (exposures) versus Nalls and colleagues4
(outcome).
Abbreviations: Chr, chromosome; Bp, base pair.
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could be applied to remaining relevant pathways in PD
as a way to better understand genetic risk factors.
Unraveling the genetics underlying PD will provide with
therapeutic options for drug discovery and ultimately
could lead to the development of effective
interventions.
Acknowledgments: We thank all of the subjects who donated their
time and biological samples to be a part of this study.
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